Guided Therapeutics (GTHP) Accounts Payables (2010 - 2025)

Guided Therapeutics has disclosed Accounts Payables across 16 years of filings, most recently posting $2.4 million for Q4 2025.

• Accounts Payables for Q4 2025 came in at $2.4 million, up 15.38% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.4 million (up 15.38% YoY), and the FY2025 annual result was $2.4 million, up 15.38% from the prior year.
• Accounts Payables came in at $2.4 million for Q4 2025 at Guided Therapeutics, up from $2.4 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $2.5 million in Q1 2022 to a low of $29000.0 in Q1 2023.
• The 5-year median for Accounts Payables is $2.2 million (2023), against an average of $1.9 million.
• Across the five-year window, Accounts Payables slumped 98.83% in 2023 and jumped 6534.48% in 2024, its largest moves.
• Guided Therapeutics' Accounts Payables stood at $87000.0 in 2021, then jumped by 2412.64% to $2.2 million in 2022, then dropped by 8.92% to $2.0 million in 2023, then increased by 5.17% to $2.1 million in 2024, then grew by 15.38% to $2.4 million in 2025.
• The last three Accounts Payables figures came in at $2.4 million (Q4 2025), $2.4 million (Q3 2025), and $2.3 million (Q2 2025), per Business Quant data.